Janssen Biotech Inc has expanded its European partnerships with a new bispecific antibody deal – this time with F-star Therapeutics Ltd of the UK. Janssen already has projects underway using bispecific technology from Genmab A/S. The deal with F-star will explore new antibody therapeutics that are both bispecific and tetravalent, meaning they simultaneously target immune and tumour cells whilst having two additional sites for antigen binding.
